Skip to main content
Caplight Logo









BrainXell Therapeutics

BrainXell Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://brainxelltx.com/

Last Round

Grant

Mar 26, 2025

Total Funding Raised

$20.17M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

BrainXell Therapeutics is a biotechnology company that develops autologous, iPSC-derived cell therapies to treat neurodegenerative diseases such as Parkinson's disease and spinal cord injuries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Government Contracts

AI Layer

Non-AI

Keywords

induced pluripotent stem celliPSCautologous cell therapystem cell therapyregenerative medicineneurodegenerative disease treatmentParkinson's disease therapydopaminergic neuronspersonalized medicinespinal cord injurycell reprogrammingdrug discovery toolsbiotech research servicescell manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BrainXell Therapeutics Comparables

Compare BrainXell Therapeutics with similar companies based on industry and business-model similarity.

BrainXell Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kenai Therapeutics
88%
Aspen Neuroscience
87%
iRegene Therapeutics
80%

BrainXell Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 26, 2025
GrantMay 1, 2023
GrantJan 26, 2023
Series BSep 13, 2021
GrantNov 1, 2016

BrainXell Therapeutics Investors

Notable investors and investment history

BrainXell Therapeutics investors
InvestorRounds
NIH RADxGrant
Discovery to ProductGrant
California Institute for Regenerative MedicineGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 85% MoM.

  • Mar 26, 2025

    $4M grant from California Institute for Regenerative Medicine

BrainXell Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BrainXell Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BrainXell Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range5
Year Founded2022
Last FundingMar 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?